117 related articles for article (PubMed ID: 14969071)
1. DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease.
Aletaha D; Smolen JS
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S169-73. PubMed ID: 14969071
[TBL] [Abstract][Full Text] [Related]
2. The Utrecht experience with different treatment strategies in early rheumatoid arthritis.
Verstappen SM; Jacobs JW; Bijlsma JW;
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S165-8. PubMed ID: 14969070
[TBL] [Abstract][Full Text] [Related]
3. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
[TBL] [Abstract][Full Text] [Related]
5. Controversies in rheumatoid arthritis glucocorticoid therapy.
Ruyssen-Witrand A; Constantin A
Joint Bone Spine; 2018 Jul; 85(4):417-422. PubMed ID: 29246530
[TBL] [Abstract][Full Text] [Related]
6. Databases of patients with early rheumatoid arthritis in the USA.
Sokka T; Willoughby J; Yazici Y; Pincus T
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
[TBL] [Abstract][Full Text] [Related]
7. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study.
Kyburz D; Gabay C; Michel BA; Finckh A;
Rheumatology (Oxford); 2011 Jun; 50(6):1106-10. PubMed ID: 21258051
[TBL] [Abstract][Full Text] [Related]
8. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
Pincus T; Yazici Y; Sokka T; Aletaha D; Smolen JS
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S179-85. PubMed ID: 14969073
[TBL] [Abstract][Full Text] [Related]
10. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options.
Svensson B; Ahlmén M; Forslind K
Clin Exp Rheumatol; 2003; 21(3):327-32. PubMed ID: 12846051
[TBL] [Abstract][Full Text] [Related]
11. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
12. The use of methotrexate in rheumatoid arthritis.
Borchers AT; Keen CL; Cheema GS; Gershwin ME
Semin Arthritis Rheum; 2004 Aug; 34(1):465-83. PubMed ID: 15305245
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
15. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
[TBL] [Abstract][Full Text] [Related]
17. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.
Tiippana-Kinnunen T; Paimela L; Kautiainen H; Laasonen L; Leirisalo-Repo M
Scand J Rheumatol; 2010; 39(1):12-8. PubMed ID: 20132065
[TBL] [Abstract][Full Text] [Related]
18. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year.
Verstappen SM; Jacobs JW; Bijlsma JW; Heurkens AH; van Booma-Frankfort C; Borg EJ; Hofman DM; van der Veen MJ;
Arthritis Rheum; 2003 Jul; 48(7):1797-807. PubMed ID: 12847672
[TBL] [Abstract][Full Text] [Related]
19. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
20. Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.
Kauppi MJ; Neva MH; Laiho K; Kautiainen H; Luukkainen R; Karjalainen A; Hannonen PJ; Leirisalo-Repo M; Korpela M; Ilva K; Möttönen T;
J Rheumatol; 2009 Feb; 36(2):273-8. PubMed ID: 19132793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
